This HTML5 document contains 55 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n10http://linked.opendata.cz/resource/drugbank/drug/DB01553/identifier/pubchem-compound/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n11http://linked.opendata.cz/resource/drugbank/drug/DB01553/identifier/pubchem-substance/
foafhttp://xmlns.com/foaf/0.1/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01553/identifier/kegg-drug/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01553/identifier/drugbank/
n5http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n16http://linked.opendata.cz/resource/drugbank/drug/DB01553/identifier/chemspider/
n17http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n19http://linked.opendata.cz/resource/drugbank/drug/DB01553/identifier/wikipedia/
n8http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n7http://www.drugs.com/international/
n15http://linked.opendata.cz/resource/atc/
n14http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01553
rdf:type
n3:Drug
n3:description
Cloxazolam is a benzodiazepine with anxiolytic, sedative/hypnotic, muscle relaxant, and antiepileptic effects. [3] It is marketed in the Argentina, Australia, Portugal, Belgium, Switzerland, Luxembourg, Germany, Taiwan and Japan -- mainly for anti-anxiety. The usual dose of cloxazolam in adults is 3-12mg/day for anti-anxiety. [3] Although less commonly noted, it has also been reported as clinically effective in the treatment of depression, schizophrenia, and neurosis. [4] As well, it has also been studied in Japan in doses of 15-30mg/day as an adjunct in the treatment of intractable epilepsy, for which it has demonstrated effectiveness. [3]
n3:generalReferences
1. Ansseau, Marc, and Remy von Frenckell. "Controlled comparison of two anxiolytic benzodiazepines, cloxazolam and bromazepam." Neuropsychobiology 24.1 (1990): 25-29 2. Boucsein, W., and G. Wendt-Suhl. "Psychological and physiological effects of cloxazolam and diazepam under anxiety-evoking and control conditions on healthy subjects (author's transl)]." Pharmacopsychiatria 15.2 (1982): 48. 3. Ito, Masatoshi, et al. "Cloxazolam treatment for patients with intractable epilepsy." Pediatric neurology 30.2 (2004): 111-114. 4. Murata, Hisashi, et al. "Metabolism of Cloxazolam. I. Distribution, Excretion and Biotransformation in Rats and Mice." Chemical & pharmaceutical bulletin 21.2 (1973): 404-414. 5. Oliveira‐Silva, Diogo, et al. "Quantification of chlordesmethyldiazepam by liquid chromatography–tandem mass spectrometry: application to a cloxazolam bioequivalence study." Biomedical Chromatography 23.12 (2009): 1266-1275.
n3:group
approved investigational
n3:halfLife
65 hours
n3:indication
Used primarily as an anti-anxiety agent. Typically used short term, and may be given as a single dose of up to 100mcg/kg to reduce anxiety and tension experienced prior to surgery.
owl:sameAs
n5:DB01553 n17:DB01553
dcterms:title
Cloxazolam
adms:identifier
n10:2816 n11:46505281 n12:DB01553 n13:D01268 n16:2714 n19:Cloxazolam
n3:mechanismOfAction
Cloxazolam is a long acting benzodiazepine. It acts as a prodrug, with pharmacologically active metabolites, which bind to to the GABAa receptor, which other benzodiazepines bind to, to illicit a physiological response. [wiki]
n3:routeOfElimination
Renal elimination.
n3:synonym
Cloxazolazepam MT 14-411 Sepazon
n3:toxicity
Drowsiness and ataxia are dose related. Central nervous system toxicity may result in respiratory depression and loss of consciousness. As such, pre-existing central nervous system depression and severe hepatic impairment are two particular contraindications for use.
n3:foodInteraction
Alcohol used in combination may enhance sedation or cause potentially fatal respiratory/cardiovascular depression.
n3:synthesisReference
Tachikawa, R., Takagi, H., Kamioka, T., Fukunaga, M., Kawano, Y. and Miyadera, T.; US. Patents 3,696,094; October 3,1972; and 3,772,371; November 13, 1973; both assigned to Sankyo Company Limited, Japan.
foaf:page
n7:cloxazolam.html
n3:IUPAC-Name
n8:271B54E6-363D-11E5-9242-09173F13E4C5
n3:InChI
n8:271B54EC-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n8:271B54EB-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n8:271B54E8-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n8:271B54E9-363D-11E5-9242-09173F13E4C5
n3:SMILES
n8:271B54EA-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n8:271B54E4-363D-11E5-9242-09173F13E4C5
n3:logP
n8:271B54E5-363D-11E5-9242-09173F13E4C5 n8:271B54E2-363D-11E5-9242-09173F13E4C5
n3:logS
n8:271B54E3-363D-11E5-9242-09173F13E4C5
n14:hasATCCode
n15:N05BA22
n3:H-Bond-Acceptor-Count
n8:271B54F2-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n8:271B54F3-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n8:271B54ED-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n8:271B54EE-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n8:271B54F0-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n8:271B54EF-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n8:271B54F1-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
24166-13-0
n3:category
n3:Bioavailability
n8:271B54F8-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n8:271B54FA-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n8:271B54FB-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n8:271B54FC-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n8:271B54F7-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n8:271B54F6-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n8:271B54F9-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n8:271B54E7-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n8:271B54F4-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n8:271B54F5-363D-11E5-9242-09173F13E4C5